



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

June 3, 2015

**Location: Learning Resource Center
Fairmeadows Room
3550 Mills Civic Parkway
West Des Moines, Iowa 50265**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Commission Business
 - a) DHS Recommendation Letter – April 2015
 - b) P&T Committee Recommendation Letter – April 2015
 - c) Second-Generation Antipsychotic Drug Use Among Medicaid-Enrolled Children: Quality-of-Care Concerns <http://oig.hhs.gov/oei/reports/oei-07-12-00320.asp>
3. IME Updates
4. Prevalence Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Mental Health Advisory Group Update
 - a) ProDUR Edits on Antipsychotics in Children
 - b) Proposed ProDUR Edits on CNS Stimulants
8. Focus Studies/Provider Education Initiatives
 - a) Prasugrel Contraindications – Follow Up
 - b) Eszopiclone Dose – Follow Up
 - c) Second Generation Antipsychotics with Anticholinergics- Initial Review
 - d) Metoclopramide Utilization Greater than 12 weeks – Initial Review
9. Public Comment (See Conflict of Interest Disclosure Form)
10. Prior Authorization

- a) Topical Antifungals for Onychomycosis – Initial Review
- b) Topical Corticosteroids – Initial Review
- c) Ivacaftor (Kalydeco[®]) – Initial Review
- d) Olaparib (Lynparza[®]) – Initial Review
- e) Idiopathic Pulmonary Fibrosis – Initial Review
- f) Edoxaban (Savaysa[®]) – Initial Review
- g) Oral Oncology Agents – Initial Review
- h) Hepatitis C Agents – Second Review
- i) CNS Stimulants & Atomoxetine – Second Review
- j) Dextromethorphan/Quinidine (Nuedexta[®]) – Second Review
- k) Chronic Pain Syndromes – Second Review
- l) Sedative/Hypnotics – Non-Benzodiazepine – Second Review

11. Miscellaneous

- a) DUR Digest Vol. 27, No. 3 –Second Review
- b) MedWatch

12. Executive Closed Session

- a) Approval of Minutes
- b) Member Profiles

13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting August 5, 2015***
Learning Resource Center
3550 Mills Civic Parkway, West Des Moines, IA, 50265**